Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

88.21USD
29 Apr 2016
Change (% chg)

$-8.79 (-9.06%)
Prev Close
$97.00
Open
$91.19
Day's High
$92.52
Day's Low
$87.81
Volume
10,369,170
Avg. Vol
4,110,861
52-wk High
$123.36
52-wk Low
$81.89

GILD.OQ

Chart for GILD.OQ

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV)... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $119,493.00
Shares Outstanding(Mil.): 1,354.64
Dividend: 0.47
Yield (%): 2.13

Financials

  GILD.OQ Industry Sector
P/E (TTM): 7.55 62.99 45.44
EPS (TTM): 11.69 -- --
ROI: 51.50 3.21 12.52
ROE: 111.16 4.47 13.40
Search Stocks

BRIEF-Gilead Sciences says European CHMP adopts positive opinion for its drug

* European chmp adopts positive opinion for gilead's taf-based single tablet regimen odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for treatment of hiv Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Apr 29 2016

BRIEF-European regulators recommends approval of Gilead's new HIV treatment

* EU Medicines Agency recommends approval of Biogen Inc and AbbVie Inc's daclizumab to treat multiple sclerosis

Apr 29 2016

Price pressure hits Gilead first quarter U.S. hepatitis C drug sales

Gilead Sciences Inc's first quarter net profit fell 18 percent as pricing pressure resulted in lower U.S. sales of hepatitis C drug Harvoni.

Apr 28 2016

BRIEF-Gilead's treatment for HIV receives marketing authorization from european commission

* European commission grants marketing authorization for Gilead's fixed-dose combination descovy (emtricitabine, tenofovir alafenamide) for treatment of HIV Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 25 2016

New AbbVie hepatitis C regimen shows high cure rates: studies

An experimental once-daily combination hepatitis C treatment being developed by AbbVie Inc demonstrated very high cure rates across a wide range of disease genotypes, according to data presented on Saturday, likely giving the company a more competitive product if approved.

Apr 16 2016

New AbbVie hepatitis C regimen shows high cure rates -studies

April 16 An experimental once-daily combination hepatitis C treatment being developed by AbbVie Inc demonstrated very high cure rates across a wide range of disease genotypes, according to data presented on Saturday, likely giving the company a more competitive product if approved.

Apr 16 2016

Drugmakers say Japan R&D spending at risk after government forces price cuts

TOKYO Global drugmakers said they could cut research spending in Japan due to new rules requiring them to slash prices on some blockbuster drugs, including Gilead Sciences Inc's highly effective but expensive hepatitis C drug, Sovaldi.

Apr 01 2016

Gilead says Merck 'deceitful' in hepatitis C drug patent fight

Gilead Sciences Inc on Wednesday will attempt to wipe out $200 million in damages for infringing two Merck & Co patents with its blockbuster hepatitis C treatments by claiming that Merck was dishonest in obtaining the patents, an argument that attorneys say could be difficult to prove.

Mar 29 2016

Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute

SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.

Mar 24 2016

Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute

SAN JOSE, Calif.,/NEW YORK A federal jury on Thursday ordered Gilead Sciences Inc to pay Merck & Co $200 million in damages for infringing two Merck patents related to a lucrative cure for hepatitis C.

Mar 24 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks